Ibalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | CD4 |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | intravenous (IV) injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 680188-33-4 |
| ATC code | none |
Ibalizumab (TMB-355[1] previously known as TNX-355) is a non-immunosuppressive monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits the viral entry process.[2] It is being investigated as an HIV entry inhibitor[3] with the ability to block both CCR5- and CXCR4-tropic viruses,[4] and is currently undergoing a Phase II clinical trial with an estimated study completion date in October 2010.[5] Specific Research is also conducted at the Aaron Diamond AIDS Research Center under the direction of David Ho.[6]
Results from a previous Phase II of ibalizumab, reported by the original developer Tanox in 2006,[4] showed that HIV-infected patients who received the drug, in combination with an optimized background regimen (OBR), maintained a considerably greater reduction in viral load and experienced a statistically significant increase in CD4+ cells than did patients given placebo in combination with OBR. Thus, pending results of further trials, it is presently one of a limited number of viable alternative strategies to contain the virus without recourse to antiretroviral drug cocktails or a vaccine.
Development
Ibalizumab is currently being developed by TaiMed Biologics but was originally developed by Tanox, now part of Genentech. As part of Genentech's takeover of Tanox, the patent for ibalizumab was sold to TaiMed Biologics, a biotech company formed in 2007 with support from the Taiwanese Government through a $20 million investment by the state-owned National Development Fund.[7][8][9]
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 50px | This antiinfective drug article is a stub. You can help ssf by expanding it. |
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
- ↑ Ibalizumab (TMB-355), TaiMed Biologics, 2009-09-09
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ TNX-355 fact sheet, AIDSmeds.com, 2006-08-25
- ↑ 4.0 4.1 Tanox Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial, AEGiS, 2006-05-02
- ↑ Dose-Response Study of Ibalizumab + OBR in Patients With HIV-1, ClinicalTrials.gov, 2008-10-30
- ↑ "David Ho: The Man Who Could Beat AIDS". Time. 2010-01-25. Retrieved 2010-05-04.
- ↑ Genentech Partners with Taiwan Company on AIDS Drug Seeking Alpha, 2007-09-18
- ↑ Government pushes biotech industry, Taipei Times, 2007-09-15
- ↑ Tanox's AIDS Drug Survives, BioHouston, 2008-04-11
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Antiinfective agent stubs
- Monoclonal antibody stubs
